<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DARIFENACIN HYDROBROMIDE</span><br/>(dar-i-fen'a-sin)<br/><span class="topboxtradename">Enablex<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic</span>; <span class="classification">muscarinic receptor antagonist</span>; <span class="classification">bladder antispasmodic </span><br/><b>Prototype: </b>Ipratropium<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>7.5 mg and 15 mg extended release tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Darifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in contraction of
         the urinary bladder smooth muscle and stimulation of salivary secretion. 
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Control of urinary incontinence due to urgency and frequency.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to the drug; severe hepatic impairment (Child-Pugh C class); urinary retention; gastric retention; uncontrolled
         narrow-angle glaucoma.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Risk of urinary retention, clinically significant bladder outflow obstruction, decreased GI motility, severe constipation,
         ulcerative colitis, myasthenia gravis, controlled narrow angle glaucoma.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Overactive Bladder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 7.515 mg qd<br/><br/><span class="impairmenttitle">Moderate Hepatic Impairment (Child-Pugh B Class)</span><br/><span class="rdage">Max dose::</span> <span class="rdroute"> PO</span> <img src="../images/special/lesserorequal.gif"/>7.5 mg qd<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that the drug is not chewed or crushed. It must be swallowed whole.</li>
<li>Note: Dosage should not exceed 7.5 mg daily with moderate hepatic impairment (i.e., Child-Pugh B class) or concurrent therapy
            with potent inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir).
         </li>
<li>Store 15°30° C (59°86° F). Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Flu-like symptoms, urinary tract infection.  <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> asthenia, dizziness. <span class="typehead">GI:</span>
<span class="speceff-common">Constipation, dry mouth, dyspepsia, nausea,</span> abdominal pain, diarrhea.  
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Potent inhibitors of CYP3A4 (e.g., <b>clarithromycin,</b>
<b>erythromycin,</b>
<b>itraconazole,</b>
<b>ketoconazole,</b>
<b>nefazodone,</b>
<b>nelfinavir,</b> and <b>ritonavir</b>) increase darifenacin levels. Darifenacin will cause additive anticholinergic effects with other <span class="classification">anticholinergic</span> drugs. Darifenacin can increase <b>digoxin</b> concentrations. <span class="typehead">Food:</span>
<b>Grapefruit juice</b> may increase darifenacin levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 1519% bioavailability. <span class="typehead">Peak:</span> 7 h. <span class="typehead">Distribution:</span> 98% protein bound. <span class="typehead">Metabolism:</span> Extensive hepatic metabolism. <span class="typehead">Elimination:</span> Renal and fecal. <span class="typehead">Half-Life:</span> 1319 h.  
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>	Monitor for adverse effects of concurrently used drugs that have a narrow therapeutic window and are metabolized by CYP26D
            (e.g., flecainide, thioridazine, or <small>TRICYCLIC ANTIDEPRESSANTS</small>).
         </li>
<li>	Lab tests: Monitor blood levels of digoxin with concurrent therapy and assess for S&amp;S of digoxin toxicity.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>	Follow directions for taking the drug (see <small>ADMINISTRATION</small>).
         </li>
<li>	Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>	Use caution in hot environments to minimize the risk of heat prostration.</li>
<li>	Report any of the following to a health care provider: difficulty passing urine, unexplained nausea, or persistent constipation.
            
         </li>
<li>	Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>